Approved antibody therapies such as trastuzumab, targeting human epidermal growth factor 2 (HER2/ERBB2), function not only by interfering with cell growth and signaling in cancer cells but also by inducing various innate immune effector processes [69]. This evidence concerns the gene ERBB2 and cancer.